Abstract:Novel coronavirus infection is a highly infectious respiratory disease, which mainly affects the lungs. The progression of this disease is probably related to the excessive release of inflammatory mediators (such as cytokines), which further causes lung deterioration resulting in acute respiratory distress syndrome and respiratory failure, seriously threatening patients’lives. Pulmonary fibrosis is a longterm pulmonary sequela faced by the survivors of critical illness from novel coronavirus infection. It is also one of important risk factors leading to the aggravation of corona virus disease 2019. This article summarizes the research advances in the pathogenesis and treatment of pulmonary fibrosis after novel coronavirus infection.
虎梅,王艳,张建银,杨静,耑冰. 新型冠状病毒感染后肺纤维化的发病机制及相关治疗[J]. 实用心电学杂志, 2023, 32(4): 283-288.
HU Mei, WANG Yan, ZHANG Jianyin, YANG Jing, ZHUAN Bing. Pathogenesis and related treatment of pulmonary fibrosis after novel coronavirus infection. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2023, 32(4): 283-288.